BractonDeal Intel
Get full access
AcquisitionOther

Ayala Pharmaceuticals, Inc. acquired target

Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.

Deal tape row

Ayala Pharmaceuticals, Inc. -> target

This merger is expected to enhance Advaxis’s portfolio of clinical assets, with Ayala’s proprietary gamma secretase inhibitors that are being developed as targeted therapies for rare and aggressive tumors.

Open source record (SEC) ↗